{"title":"鲁贝替尼对复发小细胞肺癌具有安全性和活性","authors":"","doi":"10.1158/2159-8290.CD-RW2020-053","DOIUrl":null,"url":null,"abstract":"Lurbinectedin produced responses in 35.2% of 105 patients with relapsed small-cell lung cancer.","PeriodicalId":502270,"journal":{"name":"Cancer Discovery","volume":"82 18","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lurbinectedin Is Safe and Active in Relapsed Small-Cell Lung Cancer.\",\"authors\":\"\",\"doi\":\"10.1158/2159-8290.CD-RW2020-053\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lurbinectedin produced responses in 35.2% of 105 patients with relapsed small-cell lung cancer.\",\"PeriodicalId\":502270,\"journal\":{\"name\":\"Cancer Discovery\",\"volume\":\"82 18\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/2159-8290.CD-RW2020-053\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2159-8290.CD-RW2020-053","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
